dihydroergotoxine and 1-methyl-4-(2--methylphenyl)-1-2-3-6-tetrahydropyridine

dihydroergotoxine has been researched along with 1-methyl-4-(2--methylphenyl)-1-2-3-6-tetrahydropyridine* in 1 studies

Other Studies

1 other study(ies) available for dihydroergotoxine and 1-methyl-4-(2--methylphenyl)-1-2-3-6-tetrahydropyridine

ArticleYear
Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Acta neuropathologica, 1993, Volume: 85, Issue:4

    The effects on the substantia nigra of alpha-dihydroergocryptine (DEK), a drug with strong dopaminomimetic activity, were tested with a severe 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment in monkeys. Compared with monkeys treated with MPTP alone, the animals which received DEK plus MPTP showed reduced neuronal death in the substantia nigra. The reactive astrocytes were increased in number. Moreover, several axons which were immunopositive to phosphorylated neurofilament proteins and with features similar to those of control animals were seen in the pars compacta. The findings suggest that DEK preserves neuronal morphology and brain architecture.

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Brain Diseases; Dihydroergotoxine; Dopamine Agents; Eosine Yellowish-(YS); Glial Fibrillary Acidic Protein; Hematoxylin; Macaca fascicularis; Male; MPTP Poisoning; Neurofilament Proteins; Staining and Labeling; Substantia Nigra

1993